Drug Profile
Bemcentinib - BerGenBio/Rigel Pharmaceuticals
Alternative Names: BGB 324; BGB-3234; R-428Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; Oslo University Hospital; University of Leicester; University of Texas Southwestern Medical Center
- Class Antifibrotics; Antineoplastics; Antivirals; Benzocycloheptenes; Cycloheptanes; Hepatoprotectants; Pyridazines; Pyrrolidines; Small molecules; Triazoles
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Acute myeloid leukaemia; Malignant melanoma; Malignant-mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer; Triple negative breast cancer
- Phase I/II Glioblastoma; Pancreatic cancer
- Preclinical Adult respiratory distress syndrome; Ebola virus infections; Influenza virus infections; Respiratory syncytial virus infections; Rhinovirus infections; Zika virus infection
- No development reported Chronic myeloid leukaemia; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Solid tumours